The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Enabling a new era in minimally invasive obesity treatment across Europe
Poviztra is a second brand of Wegovy
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Subscribe To Our Newsletter & Stay Updated
